Abemaciclib, mai hana aromatase, Eli Lilly da kamfanin, endocrine far, Tamoxifen, Verzenio
Abemaciclib tare da maganin endocrin an yarda da FDA a cikin HER 2 tabbataccen ciwon nono
Maris 2023: Abemaciclib (Verzenio, Eli Lilly da Kamfani) da kuma maganin endocrine (tamoxifen ko mai hana aromatase) Hukumar Abinci da Magunguna (FDA) ta amince da ita don kula da tsofaffi marasa lafiya tare da ..
CAR T Gwajin Kwayoyin Jiyya, Glioblastoma, gwajin glioblastoma, gliomas
Tsaro da Ingantaccen Nazarin Anti-B7-H3 CAR-T Cell Therapy don Maimaitawa Glioblastoma
March 2023: Study Type : Interventional (Clinical Trial)Estimated Enrollment : 30 participantsAllocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: a "3+3" design is used to determine Maximum..
Americanungiyar Hematology ta Amurka, Karteyva, Sin, JW Therapeutics, relmacabtagene autoleucel
JW Therapeutics Yana Gabatar da Sabbin Bayanan Clinical akan Carteyva® a cikin Follicular Lymphoma da Mantle Cell Lymphoma a Taron Shekara-shekara na ASH na 64th
SHANGHAI, CHINA, Disamba 12, 2022 Wani kamfani mai zaman kansa kuma mai ƙirƙira na fasahar kere kere mai suna JW Therapeutics (HKEX: 2126) yana mai da hankali kan haɓakawa, ƙira, da siyar da samfuran rigakafin ƙwayoyin cuta. A taron jama'ar Amirka na 64.
dMMR, Dostarlimab-gxly, GlaxoSmithKline, Jemperli
Dostarlimab-gxly ta amince da FDA don ciwon daji na endometrial dMMR
Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) an bai wa FDA izinin kula da manya marasa lafiya da rashin daidaituwa na gyara (dMMR) maimaituwa ko ci gaba da ciwon daji na endometrial wanda ya ci gaba a lokacin ko bayan kafin ..
Daichi Sankyo, KADDARA-NONO04, Enhertu, fam-trastuzumab deruxtecan-nxki
Fam-trastuzumab deruxtecan-nxki ta amince da FDA don HER2-ƙananan ciwon nono
Agusta 2022: Ga marasa lafiya marasa lafiya waɗanda ba a iya gano su ba ko kuma metastatic HER2-low (IHC 1+ ko IHC 2+/ISH) kansar nono waɗanda suka karɓi chemotherapy kafin a cikin yanayin metastatic ko kuma sun sami sake dawowar cuta yayin ko tsakanin shida.
AstraZeneca Pharmaceuticals, BRCA, gBRCAm, Lynparza, olaparib, OlympiA
An amince da Olaparib don maganin cutar kansa mai haɗari da wuri
Maris 2022: Hukumar Abinci da Magunguna ta amince da olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) don kula da tsofaffi marasa lafiya tare da lalata ko ake zargi da lalata germline BRCA-mutated (gBRCAm) h..
Atezolizumab, Bevacizumab, nivolumab, Regorfenib, Stivarga, Tecentriq
Magungunan da aka yarda don maganin ciwon hanta
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-S-M..
FDA, Saukewa: KRAS G12C, Lumakras, Bayanin NSCLC, sotorasib
FDA ta amince da maganin farko da aka yi niyya don maye gurbin cutar kansar huhu wanda a baya ake tunanin ba zai iya jurewa da magani ba
20 ga Agusta, 2021: Kwanan baya a watan Mayu, 2021 Lumakras (sotorasib) Hukumar Abinci da Magunguna ta Amurka ta amince da ita a matsayin magani na farko ga tsofaffi marasa lafiya da ƙananan ƙwayoyin cutar huhu na huhu waɗanda suka sha aƙalla tsarin farko ɗaya.
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, KARANTA, USFDA
Pembrolizumab ya amince da FDA don adjuvant magani na melanoma
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..
Ablynx, ADAMUTA 13, CABLIVI, caplacizumab-yhdp, FDA, immunosuppressive far, USFDA
Caplacizumab-yhdp ta amince da FDA
A ranar 6 ga Fabrairu, 2019, tare da musayar plasma da maganin rigakafi, Cibiyar Abinci da Magunguna ta amince da caplacizumab-yhdp (CABLIVI, Ablynx NV) ga marasa lafiya manya da suka samu thrombotic thrombocytopeni ..